Business
REPLACEMENT: Total Voting Rights
REPLACEMENT: Total Voting Rights.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 7685X Oxford Biomedica PLC 01 May 2019 \n\n \n \n \nOxford Biomedica \nTotal Voting Rights\n \n \nThe 'Total Voting Rights' announcement released today at 11:33 under RNS No 7565X contained an incorrect figure and is replaced by this announcement.\n \nOxford, UK - 1 May 2019: Oxford Biomedica plc (\"Oxford Biomedica\" or \"the Company\") (LSE: OXB), announces that in accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1, the Company's issued share capital as at the close of business on 30 April 2019 consisted of 68,863,354 ordinary shares of 50 pence each (\"Ordinary Shares\"). There are no Ordinary Shares held in treasury. \n \nAccordingly, the total number of voting rights in Oxford Biomedica plc at the date of this notice is 68,863,354.\n \nThe above figure (68,863,354) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford Biomedica plc under the FCA's Disclosure and Transparency Rules.\n \n-Ends-\n \n\n\n\nFor further information, please contact:\n\n\n \n\n\n\n\n \nOxford Biomedica plc:\nStuart Paynter, Company Secretary\n\n\n \nTel: +44 (0)1865 783 000\n\n\n\n \n \nAbout Oxford Biomedica\n \nOxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the \"Group\") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 430 people. Further information is available ...